New FDA Guidance Clinical Trial Considerations To Support Accelerated Approval Of Oncology Therapeutics
On April 6, 2023, AbbVie announced that it was voluntarily withdrawing ibrutinib, which was granted accelerated approval for two indications: mantle...
Marjoriee Zettler Drug Administration Oncologic Drugs Advisory Committee Regor Pharmaceuticals Inc Drug Administration Expedited Development Us Government Accountability Office
Source: lifescienceleader.com